Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy.
Helena Van DammeBruno DombrechtMáté KissHeleen RooseElizabeth AllenEva Van OvermeireDaliya KanchevaLiesbet MartensAleksandar MurgaskiPauline Madeleine Rachel BardetGillian BlanckeMaude JansEvangelia BolliMaria Solange MartinsYvon ElkrimJames DooleyLouis BoonJulia Katharina SchwarzeFrank TackeKiavash MovahediNiels VandammeBart NeynsSebahat OcakIsabelle ScheyltjensLars VereeckeFrank Aboubakar NanaPascal MerchiersDamya LaouiJo Agnes Van GinderachterPublished in: Journal for immunotherapy of cancer (2022)
Collectively, our findings highlight the efficacy and safety of targeting CCR8 for the depletion of tumor-promoting ti-Tregs in combination with anti-PD-1 therapy.